Larimar Therapeutics
LRMR
89 hedge funds and large institutions have $304M invested in Larimar Therapeutics in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 45 increasing their positions, 21 reducing their positions, and 10 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 21
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
17% more capital invested
Capital invested by funds: $260M → $304M (+$44M)
2% more funds holding
Funds holding: 87 → 89 (+2)
1.77% less ownership
Funds ownership: 7.65% → 5.88% (-1.8%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
94% less call options, than puts
Call options by funds: $7K | Put options by funds: $126K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.6M |
| 2 |
BlackRock
New York
|
+$6.92M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$6.55M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.52M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$3.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$16.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 3 |
AG
Artal Group
Luxembourg
|
-$4.05M |
| 4 |
AC
Armistice Capital
New York
|
-$3.4M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.56M |
LRMR Hedge Fund Activity: Q3 2018 in Review
89 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2018, worth a combined $304M — up 17% from $260M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new LRMR positions and 10 closed out — a net gain of 2 holders — while 45 added to existing stakes and 21 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $12.6M. The largest seller was 683 Capital Management, exiting entirely with an estimated $16.4M sold.
- 89 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2018, up from 87 in Q2 2018.
- Funds reported $304M of Larimar Therapeutics stock for Q3 2018, up 17% quarter-over-quarter.
- 12 funds opened new Larimar Therapeutics positions in Q3 2018 and 10 closed out, a net change of +2 holders.
- The largest Larimar Therapeutics buyer in Q3 2018 was T. Rowe Price Associates, an estimated $12.6M added.
- The largest Larimar Therapeutics seller in Q3 2018 was 683 Capital Management, an estimated $16.4M sold.
Based on aggregated 13F filings for Q3 2018.